A New Class of Drugs Arrives for Multiple Myeloma
The U.S. Food and Drug Administration granted accelerated approval to iberdomide, sold under the brand name Zenbexus, in August 2026. This decision introduces the first drug from a new therapeutic class known as cereblon E3 ligase modulators, or CELMoDs, for the treatment of relapsed or refractory multiple myeloma. For patients whose cancer has returned or stopped responding to previous treatments, this approval offers a new option within a combination therapy that includes daratumumab and dexamethasone.
The approval is significant because it moves a novel mechanism of action into standard clinical practice. Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow. When the disease becomes relapsed or refractory, treatment options can become limited, and finding a regimen that controls the disease effectively is a primary concern for both patients and physicians. The FDA’s decision relies on data showing that the new combination produces higher rates of minimal residual disease negativity compared to a standard of care regimen. This means that in a larger proportion of patients, the treatment was able to reduce the cancer to levels that are difficult to detect with sensitive testing.
Development and Background of Iberdomide
Iberdomide was developed by Bristol Myers Squibb and is classified as a thalidomide analog. While it shares its lineage with older immunomodulatory agents, it is designed to act as a protein degrader with distinct properties. Iberdomide has a higher binding affinity than lenalidomide or pomalidomide, two drugs that have been mainstays in myeloma treatment for years. This increased affinity is intended to allow the drug to bind more potently to the cereblon protein and activate the immune system more strongly than previous immunomodulatory drugs.
The drug has undergone clinical trials for various cancers and was also tested in people with lupus, indicating a broader area of research interest. However, its current approval is specific to multiple myeloma. The FDA granted the application for iberdomide priority review, breakthrough therapy, and orphan drug designations, reflecting the agency’s recognition of the drug’s potential to address an unmet medical need in a serious condition. These designations often expedite the review process for drugs treating rare or life-threatening diseases where no satisfactory treatment exists.
How the Drug Works: The CELMoD Mechanism
To understand why this approval is noteworthy, it is helpful to look at the mechanism of action. Traditional immunomodulatory drugs bind to the cereblon protein, which is part of an E3 ubiquitin ligase complex. This complex tags specific proteins for degradation. Iberdomide, as a CELMoD, modulates this process to degrade proteins that are critical for the survival of myeloma cells. By removing these survival proteins, the drug helps the immune system recognize and attack the cancer cells.
Jesús Berdeja, MD, of Sarah Cannon Research Institute and Tennessee Oncology, noted that CELMoDs bind cereblon more potently and activate the immune system more strongly than standard immunomodulatory drugs. This difference in potency and immune activation is the theoretical basis for the improved outcomes seen in clinical trials. The drug is taken orally, which adds to its practicality for patients who may be managing a chronic condition. The dosing schedule involves taking 1.0 mg daily on days 1 through 21 of a 28-day cycle, alongside the other components of the combination therapy.
Clinical Trial Data from EXCALIBER-RRMM
The FDA’s decision was based primarily on the results of the phase 3 EXCALIBER-RRMM trial, identified by the clinical trial number NCT04975997. This was a multicenter, open-label study that evaluated iberdomide plus daratumumab and dexamethasone against a standard regimen of daratumumab, bortezomib, and dexamethasone, known as DVd. The trial enrolled patients with relapsed or refractory multiple myeloma who had received one or two prior lines of therapy. Importantly, patients with disease refractory to prior anti-CD38 monoclonal antibody therapy or to prior bortezomib were excluded from the study.
The primary endpoint for the accelerated approval was the rate of minimal residual disease (MRD) negative complete response. MRD negativity is a measure of how much cancer remains in the body, detected at very low levels, often at a sensitivity of 10 to the power of negative five. In the interim analysis of the trial, the MRD-negative complete response rate was 41% in the iberdomide combination arm, compared to 21% in the DVd arm. This difference was statistically significant, with a P-value of less than .0001. The confidence interval for the iberdomide arm was 34% to 48%, while for the DVd arm, it was 15% to 27%.
Sagar Lonial, MD, the lead investigator of the EXCALIBER-RRMM trial and chief medical officer of the Winship Cancer Institute of Emory University, stated in a news release that the approval marks the anticipated arrival of a new therapeutic class. He noted that the strong results observed with the CELMoD-based combination within a familiar triplet approach creates the potential for a new treatment foundation in multiple myeloma. The trial included 939 participants randomized to different dose levels in the first stage and to the final 1 mg dose in the second stage. The data monitoring committee recommended the continuation of the trial based on these positive initial findings.
Patient Qualifications, Side Effects, and Precautions
Not all patients with multiple myeloma are eligible for this treatment. According to the prescribing information, iberdomide is indicated for adults who have received at least one prior line of therapy that included a proteasome inhibitor and an immunomodulatory agent. This specific history ensures that the drug is used in the appropriate clinical context where it has been tested and shown to be effective. Patients should discuss their specific treatment history with their hematologist-oncologist to determine if this regimen is suitable for them.
The prescribing information includes boxed warnings, which are the most serious warnings issued by the FDA. These include risks of embryo-fetal toxicity and serious venous and arterial thromboembolism. Embryo-fetal toxicity means that the drug can cause harm to a developing fetus if taken during pregnancy. Because of this risk, iberdomide is only available through a Risk Evaluation and Mitigation Strategy, or REMS. This program is designed to ensure that the potential benefits of the drug outweigh the risks for each individual patient and that appropriate precautions are taken to prevent exposure during pregnancy.
Other common adverse effects include neutropenia, which is a low count of neutrophils, a type of white blood cell that helps fight infection. Infections are also a noted risk, as are secondary primary malignancies, which are new cancers that may develop later. The combination therapy also involves daratumumab and hyaluronidase, which is given subcutaneously, and dexamethasone, which is taken orally. The dosing of dexamethasone varies, with 20 mg or 40 mg given on specific days of the cycle. Patients should be aware that while the iberdomide component is oral, the full regimen involves multiple medications with different administration routes and schedules.
What the Data Does and Does Not Show
It is important to understand the limitations of the accelerated approval. The FDA relied on MRD negativity as a surrogate endpoint for this decision. This means that the approval was based on the assumption that achieving MRD negativity will likely lead to longer progression-free survival and overall survival. However, data on progression-free survival and overall survival remain pending. The trial is ongoing, and these long-term outcomes will be reported in the future. Until then, the 41% versus 21% difference in MRD negativity is the key metric supporting the approval.
Patients should be cautious about interpreting this as a cure. Multiple myeloma is a complex disease, and while the results are encouraging, they do not guarantee that every patient will respond or that the disease will be permanently controlled. The trial excluded patients with refractory disease to anti-CD38 antibodies or bortezomib, so the results may not apply to those specific populations. Additionally, the sample size, while substantial for a phase 3 trial, is not infinite, and individual responses can vary. The encouraging part is that a new class of drugs has entered the arsenal against multiple myeloma, offering hope for better disease control in the relapsed or refractory setting.
For patients and families navigating this diagnosis, the arrival of iberdomide represents a significant step forward in treatment options. The data from the EXCALIBER-RRMM trial suggests that this new mechanism can achieve higher rates of deep remission than previous standards. However, medical decisions are personal and depend on individual health factors, prior treatments, and overall goals of care. The best course of action is to talk to your doctor or oncologist. They can review your specific medical history, explain the potential benefits and risks of the iberdomide combination, and help you make an informed decision about your treatment plan. Understanding the new options available is a crucial part of managing multiple myeloma, and having an open conversation with your healthcare team is the best way to move forward with confidence.
Sources
- FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma | Targeted Oncology – Immunotherapy, Biomarkers, and Cancer Pathways
- FDA Approves Iberdomide Combo in Relapsed/Refractory Multiple Myeloma | CancerNetwork
- Iberdomide
- Five Under 5: Top Oncology Videos for the Week of 10/12 | OncLive
Photo: Subhrajyoti07 (CC BY-SA 4.0)
